A Mobile Phone Based Medication Reminder Program
27 de enero de 2017 actualizado por: Duke University
A Mobile Phone Based Medication Reminder Program for Patients in China With Coronary Heart Disease: A Pilot Study
This study evaluates the feasibility and acceptability of using mobile applications to improve medication adherence.
Participants in the experimental group will receive educational materials and daily reminders through mobile applications.
While, participants in the control group will receive only educational materials.
After the intervention, interviews will be conducted among participants through phone calls.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
The purpose of this study is to improve medication adherence for Chinese patients with coronary heart disease (CHD) by using mobile applications.
An exploratory randomized controlled trial (RCT, N=49) and interviews (n=15) will be included in this pilot study.
The RCT will compare the effects of the medication adherence (MA, n=24) intervention and control condition (n=25) on the MA score (percent of prescribed antihypertensive drugs taken), and health outcomes (SBP and DBP obtained) of patients.
The health outcomes will be assessed at enrollment and every three days after the intervention begins for thirty days.
Feasibility will be determined by the number of patients enrolled, and retention (percent of patients who complete the study).
Acceptability (read daily reminders and educational materials via mobile applications) will be evaluated through focus group interviews.
All analyses will be performed using SAS 9.3 (Cary, NC).
The potential risks of this study are minimal.
Tipo de estudio
Intervencionista
Inscripción (Actual)
49
Fase
- No aplica
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion criteria for participants are:
- having a medical diagnosis of CHD
- being eighteen years old or older
- having an antihypertensive medication regimen that lasts for forty-nine days or more at the enrollment
- being able to read messages through mobile phone
- having a mobile phone which can receive messages from WeChat, and can receive daily reminders from BB Reminder
- having no obvious cognitive impairment
- patients with comorbidities can be included in the study, but during the study, antihypertensive medications are their only prescribed medications (this will be screened by the cardiologist).
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Mobile App Group
Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
|
Reminders.
Participants will receive medication-taking reminders from the researcher.
These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher).
BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications.
The daily reminders will be sent to participants 15 minutes before every dose of their medications.
Educational materials.
Participants will receive educational materials from the researcher.
These educational materials will be sent through the mobile application-WeChat.
The educational materials include short articles (< 500 words) and/or pictures.
They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health.
The validity of information from it is guaranteed.
The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants.
The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
|
|
Comparador activo: Control Group
The control group will receive the same educational materials, but no daily reminder.
|
Educational materials.
Participants will receive educational materials from the researcher.
These educational materials will be sent through the mobile application-WeChat.
The educational materials include short articles (< 500 words) and/or pictures.
They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health.
The validity of information from it is guaranteed.
The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants.
The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in medication adherence score
Periodo de tiempo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
Percent of prescribed antihypertensive drugs taken during the past three days.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
|
Change in systolic blood pressure (SBP)
Periodo de tiempo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
|
|
Change in diastolic blood pressure (DBP)
Periodo de tiempo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility as measured by patient enrollment
Periodo de tiempo: approximately seven weeks
|
Feasibility will be determined by the number of patients enrolled, and retention (percent of patients who complete the study).
|
approximately seven weeks
|
|
Feasibility as measured by patient retention
Periodo de tiempo: approximately seven weeks
|
Feasibility will be determined by retention (percent of patients who complete the study)
|
approximately seven weeks
|
|
Acceptability as measured by patient interviews
Periodo de tiempo: approximately seven weeks
|
Acceptability (read daily reminders and educational materials via mobile applications) will be evaluated through interviews.
|
approximately seven weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
11 de julio de 2016
Finalización primaria (Actual)
19 de septiembre de 2016
Finalización del estudio (Actual)
12 de noviembre de 2016
Fechas de registro del estudio
Enviado por primera vez
3 de junio de 2016
Primero enviado que cumplió con los criterios de control de calidad
7 de junio de 2016
Publicado por primera vez (Estimar)
8 de junio de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
30 de enero de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
27 de enero de 2017
Última verificación
1 de enero de 2017
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Pro00073395
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .